Sign In
Buy ALRN
$2.11
+0 (+0%)
At Close: Apr 09, 2025
Hedge Fund Sentiment Is Unchanged On Aileron Therapeutics, Inc. (ALRN)
10:45pm, Friday, 20'th Dec 2019
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (u
Are Insiders Buying Aileron Therapeutics, Inc. (NASDAQ:ALRN) Stock?
11:07am, Thursday, 19'th Dec 2019
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
Aileron Therapeutics Announces the Promotion of Richard J. Wanstall to Chief Financial Officer and Treasurer
01:30pm, Wednesday, 18'th Dec 2019
Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, announced today the promotion of Richard J. Wanstall to Chief Financial Officer and Treasur
Aileron Therapeutics Reports Third Quarter 2019 Results
12:30pm, Thursday, 07'th Nov 2019
Announced positive interim results from its ongoing Phase 2a clinical trial evaluating the combination of ALRN-6924 and Pfizer’s IBRANCE® (palbociclib) for the treatment of.
Aileron Therapeutics to Report Third Quarter 2019 Financial Results on November 7th
12:30pm, Thursday, 31'st Oct 2019
WATERTOWN, Mass., Oct. 31, 2019 -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, today announced that the.
Aileron Therapeutics Announces Positive Nonclinical Myelopreservation Results for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference
12:00pm, Tuesday, 29'th Oct 2019
Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, presented new data at the 2019 AACR-NCI-EORTC Conference from nonclinical studies in which
Aileron to Present Nonclinical Myelopreservation Data for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference on October 29th
12:00pm, Monday, 21'st Oct 2019
Nonclinical research showed that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells without inhibiting the anti-cancer activity of chemotherapy..
Treatment uses a precision-medicine strategy to prevent the toxic side-effects of chemotherapy in patients with p53-mutated cancer, representing approximately 50% of all patients with cancer. Managem
